| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
| (30) |
Priority: |
15.07.2002 US 396290 P
20.06.2003 US 480043 P
|
| (43) |
Date of publication of application: |
|
19.10.2005 Bulletin 2005/42 |
| (60) |
Divisional application: |
|
10176072.6 / 2263691 |
| (73) |
Proprietor: F.Hoffmann-La Roche AG |
|
4070 Basel (CH) |
|
| (72) |
Inventors: |
|
- KOLL, Hans
85247 Oberroth (DE)
- BOSSENMAIER, Birgit
82229 Seefeld (DE)
- MÜLLER, Hans-Joachim
82377 Penzberg (DE)
- SLIWKOWSKI, Mark, X.
San Carlos, CA 94070 (US)
- KELSEY, Stephen, Michael
Montara, CA 94037 (US)
|
| (74) |
Representative: Walton, Seán Malcolm et al |
|
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS
London
EC2V 8AS (GB) |
| (56) |
References cited: :
WO-A-01/00245
WO-A-01/89566
US-A- 5 811 098
US-B1- 6 417 168
|
WO-A-01/09186
US-A- 5 811 098
US-A1- 2002 064 805
US-B1- 6 417 168
|
|
| |
|
|
- XIA W ET AL: "Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for
the outcome of oral squamous cell carcinoma than any individual family members." CLINICAL
CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.
DEC 1999, vol. 5, no. 12, December 1999 (1999-12), pages 4164-4174, XP002400085 ISSN:
1078-0432
- GILBERTSON RICHARD J ET AL: "Prognostic significance of HER2 and HER4 coexpression
in childhood medulloblastoma" CANCER RESEARCH, vol. 57, no. 15, 1997, pages 3272-3280,
XP008069241 ISSN: 0008-5472
- LANE HEIDI A ET AL: "ErbB2 potentiates breast tumor proliferation through modulation
of p27Kip1-Cdk2 complex formation: Receptor overexpression does not determine growth
dependency" MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 9, May 2000 (2000-05), pages
3210-3223, XP002400087 ISSN: 0270-7306
- LYNE J C ET AL: "Tissue expression of neu differentiation factor/heregulin and its
receptor complex in prostate cancer and its biologic effects on prostate cancer cells
in vitro." THE CANCER JOURNAL FROM SCIENTIFIC AMERICAN. 1997 JAN-FEB, vol. 3, no.
1, January 1997 (1997-01), pages 21-30, XP002400088 ISSN: 1081-4442
- OLAYIOYE M: "The Erbbeta Signaling Network: Receptor Heterodimerization in Development
and Cancer" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 13, January
2000 (2000-01), pages 3159-3167, XP002985171 ISSN: 0261-4189
- MOTOYAMA ANDREA B ET AL: "The efficacy of ErbB receptor-targeted anticancer therapeutics
is influenced by the availability of epidermal growth factor-related peptides" CANCER
RESEARCH, vol. 62, no. 11, 11 June 2002 (2002-06-11), pages 3151-3158, XP001155498
ISSN: 0008-5472
- CHEN XINMEI ET AL: "Enhanced drug resistance in cells coexpressing ErbB2 with EGF
receptor or ErbB3" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 277,
no. 3, 2 November 2000 (2000-11-02), pages 757-763, XP002400090 ISSN: 0006-291X
- BROCKHOFF GERO ET AL: "Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor
interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma
cells" CYTOMETRY, vol. 44, no. 4, 1 August 2001 (2001-08-01), pages 338-348, XP002400091
ISSN: 0196-4763
- NEVE RICHARD M ET AL: "Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast
tumour cells" ONCOGENE, vol. 19, no. 13, 23 March 2000 (2000-03-23), pages 1647-1656,
XP002400092 ISSN: 0950-9232
- AGUS D.B. ET AL: 'Targeting ligand-activated ErbB2 signaling inhibits breast and prostate
tumor growth' CANCER CELL vol. 2, August 2002, pages 127 - 137, XP002988666
- TZAHAR E. ET AL: 'The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood
to multiple stromal ligands' BIOCHEMICA ET BIOPHYSICA ACTA vol. 1377, 20 February
1998, pages M29 - M34, XP004281795
- SLIKOWSKI M.X. ET AL: 'Coexpression of erbB2 and erbB3 proteins reconstitutes a high
affinity receptor for heregulin' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 269, no.
20, 20 May 1994, pages 14661 - 14665, XP000605388
- QIAN X. ET AL: 'p185c-neu and Epidermal Growth Factor Receptor Associated into Structure
Composed of Activated Kinases' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol.
89, February 1992, pages 1330 - 1334, XP002988667
- GORDON MICHAEL S ET AL: "Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization
inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor
HER2 activation status", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL
ONCOLOGY, US, vol. 24, no. 26, 10 September 2006 (2006-09-10), pages 4324-4332, XP002492090,
ISSN: 0732-183X, DOI: DOI:10.1200/JCO.2005.05.4221 [retrieved on 2006-08-07]
- BASELGA, J. ET AL.: "Objective response rate in a phase II multicenter trial of pertuzumab
(P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuuzumab
(T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which as progressed
during treatment with T", JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 20 June
2007 (2007-06-20), page 1004,
- MAKHIJA, S. ET AL.: "Results from a phase II randomzied, placebo-controlled, double-blind
trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients
with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer", JOURNAL
OF CLINICAL ONCOLOGY, vol. 25, no. 18S, 20 June 2007 (2007-06-20), page 5507,
- CHEE M NG ET AL: "Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based
on Population Pharmacokinetic Analysis", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC
PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 23, no. 6, 26 May 2006 (2006-05-26), pages
1275-1284, XP019405128, ISSN: 1573-904X, DOI: DOI:10.1007/S11095-006-0205-X
- ALLISON, D. ET AL,: "Pharmacokinetics (PK) of Pertuzumab (rhuMAb 2C4) in Phase II
Studies of Ovarian, Breast, Prostate, and Lung Cancers", , 2005, page 2532,
|
|
